Dosage: Memantine starting dosage is 5 mg daily, which can slowly be tapered up to 10-15 mg, depending on the indication.
Note: Memantine half-life is 60-100 hours, therefore caution should be exerted when tapering up after first days of use.
Side effects: Memantine is, in general, well-tolerated. Side effects are likely to occur if the dosage accumulated in the body is too high. The side effects include confusion, drowsiness, headache, agitation and hallucination.
Country of Manufacture: Russia
Availability: in stock
Synthesised by Eli Lilly and Company in 1968, Memantine is one of the few pharmaceuticals approved by FDA for treatment of moderate-to-severe Alzheimer's disease. Off-label use of Memantine also includes reversing tolerance for caffeine, nicotine and opioids; it might also be taken for a treatment of generalised anxiety disorder.
In the body Memantine reduces certain types of brain activity by binding to NMDA receptors and blocking the activity of glutamate. As a result, Memantine upregulates receptors in the brain and has a cognitive-enhancing effect.
Country of Manufacture: Russia
- M Rogawski, G Wenk (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease https://www.ncbi.nlm.nih.gov/pubmed/14530799
- Reisberg et al (2003) Memantine in moderate-to-severe Alzheimer's disease https://www.ncbi.nlm.nih.gov/pubmed/12672860
- Mobius et al (2004) Memantine hydrochloride: pharmacological and clinical profile https://www.ncbi.nlm.nih.gov/pubmed/15510240
- R Tampi, C van Dyck (2007) Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654628/
- Charles et al (2007) Memantine for prevention of migraine: a retrospective study of 60 cases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3451671/
- H Kavirajan, L Schneider (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials https://www.ncbi.nlm.nih.gov/pubmed/17689146
- Farlow et al (2008) Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials https://www.ncbi.nlm.nih.gov/pubmed/18558791
- Porsteinsson et al (2008) Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial https://www.ncbi.nlm.nih.gov/pubmed/18288936
- Clerici et al (2009) Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study https://www.ncbi.nlm.nih.gov/pubmed/19476399
- S Thomas, G Grossberg (2009) Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762361/
- Howard et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease https://www.ncbi.nlm.nih.gov/pubmed/22397651
- Yang et al (2013) Effectiveness and safety of memantine treatment for Alzheimer's disease https://www.ncbi.nlm.nih.gov/pubmed/23635410
- Dysken et al (2014) Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease The TEAM-AD VA Cooperative Randomized Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109898/
- Nakamura et al (2014) Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025599/
- Matsunaga et al (2015) Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis https://www.ncbi.nlm.nih.gov/pubmed/25860130
- Atri et al (2015) Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436119/
- Hager et al (2016) Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study https://www.ncbi.nlm.nih.gov/pubmed/27846868
- Marimuthu et al (2016) Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: A double-blind placebo-controlled clinical trial (Phase IIIb pilot study) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980957/
- Kishi et al (2017) Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis https://www.ncbi.nlm.nih.gov/pubmed/28922160
- Karahmadi et al (2017) Study of the effect of Memantine therapy on the treatment of dyslexia in children https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767814/
- N Titova et al (2017) Memantine: from the original brand to generics https://www.ncbi.nlm.nih.gov/pubmed/29171502
- Folch et al (2018) Memantine for the Treatment of Dementia: A Review on its Current and Future Applications https://www.ncbi.nlm.nih.gov/pubmed/29254093
- Tavakoli-Ardakani et al (2018) Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958331/